ORLANDO, Fla.--(BUSINESS WIRE)--Pfizer announced today that Lipitor® (atorvastatin calcium) Tablets (80 mg) was more effective than simvastatin (20 mg–40 mg) in reducing the risk of multiple cardiovascular events in patients with a history of heart attacks in the Incremental Decreases through Aggressive Lipid Lowering (IDEAL) clinical trial.
Cardiovascular events included heart attack, stroke, and cardiac revascularization procedures such as bypass surgery and angioplasty. The results were presented at the Annual Scientific Sessions of the American Heart Association.
